CN104147255A - Pharmaceutical composition for treatment of severe pulmonary infection - Google Patents
Pharmaceutical composition for treatment of severe pulmonary infection Download PDFInfo
- Publication number
- CN104147255A CN104147255A CN201410417795.6A CN201410417795A CN104147255A CN 104147255 A CN104147255 A CN 104147255A CN 201410417795 A CN201410417795 A CN 201410417795A CN 104147255 A CN104147255 A CN 104147255A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- pharmaceutical composition
- radix
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a pharmaceutical composition for treatment of severe pulmonary infection. The pharmaceutical composition contains the components in parts by weight: 5-20 parts of radix astragali, 1-10 parts of angelica sinensis, 1-5 parts of raw radix rehmanniae, 1-10 parts of folium isatidis, 1-5 parts of fructus forsythia and the like. The medicines are in mutual influence and synergistic effect, and thus the pharmaceutical composition plays quite good effects of dispelling wind and heat, clearing lung and relieving exterior syndromes, and detoxifying and reducing phlegm, has a quite good therapeutic effect on severe pulmonary infection, and has the advantages of simple raw materials, low cost, and convenient taking.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of pharmaceutical composition for the treatment of severe pulmonary infection.
Background technology
Severe pulmonary infection refers to that patient is except the common Respiratory symptoms of pneumonia, sign, the performance that still has respiratory failure and other system obviously to get involved.Advocate at present to adopt the principle of " weight is fiercelyed attack " to give effective antibiotic and treat as early as possible, but for treating with antibiotic etc., easily make pathogenic bacteria produce drug resistance.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of severe pulmonary infection.
In order to realize object of the present invention, the invention provides a kind of pharmaceutical composition for the treatment of severe pulmonary infection, the material that it comprises following weight portion: Radix Astragali 5-20 part, Radix Angelicae Sinensis 1-10 part, Radix Rehmanniae 1-5 part, Folium Isatidis 1-10 part and Fructus Forsythiae 1-5 part.
Preferably, the material that the pharmaceutical composition of described treatment severe pulmonary infection comprises following weight portion: 3 parts of 8 parts of the Radixs Astragali, 6 parts of Radix Angelicae Sinensis, 3 parts of Radix Rehmanniae, 2 parts of Folium Isatidiss and Fructus Forsythiaes.
Preferably, the pharmaceutical composition of described treatment severe pulmonary infection also comprises the material of following weight portion: Herba basellae rubrae 5-20 part, Radix Asparagi 1-10 part, Radix Ranunculi Ternati 10-30 part, Flos Hibisci 1-5 part, Herba Limnophilae rugosae 1-20 part, Herba Violae diffusae 10-30 part, Herba Commelinae Diffusae 1-20 part, Herba Astragali Sinici 10-30 part, Flos Inulae 1-10 part, Herba Solidaginis 5-15 part, Herba Violae 10-30 part, cold certain kind of berries 1-10 part, Cacumen Myricariae Germanicae 1-5 part, Semen Sojae Preparatum seven 5-10 parts, Semen Sojae Preparatum 1-10 part, Herba Eupatorii Lindleyani 20-50 part, Herba Spilanthis Acmellae 1-10 part and Cor Cervi grass 1-10 part.
Preferably, the pharmaceutical composition of described treatment severe pulmonary infection also comprises the material of following weight portion: 10 parts of Herba basellae rubrae, 7 parts of Radix Asparagi, 15 parts of Radix Ranunculi Ternatis, 3 parts of Flos Hibisci, 10 parts of Herba Limnophilae rugosaes, 11 parts of Herba Violae diffusaes, 10 parts of Herba Commelinae Diffusaes, 15 parts of Herba Astragali Sinici, 5 parts of Flos Inulaes, 9 parts of Herba Solidaginiss, 15 parts of Herba Violaes, 9 parts of the cold certain kind of berries, 3 parts of Cacumen Myricariae Germanicaes, 77 parts of Semen Sojae Preparatums, 7 parts of Semen Sojae Preparatums, 30 parts of Herba Eupatorii Lindleyanis, 8 parts of Herba Spilanthis Acmellae, 9 parts of Cor Cervi grass.
Preferably, described pharmaceutical composition can be tablet, dispersible tablet, capsule, soft capsule or decoction.
The present invention also provides the application of pharmaceutical composition in the medicine of preparation treatment severe pulmonary infection, the material that described pharmaceutical composition comprises following weight portion: Radix Astragali 5-20 part, Radix Angelicae Sinensis 1-10 part, Radix Rehmanniae 1-5 part, Folium Isatidis 1-10 part and Fructus Forsythiae 1-5 part.
Preferably, the material that described pharmaceutical composition comprises following weight portion: 3 parts of 8 parts of the Radixs Astragali, 6 parts of Radix Angelicae Sinensis, 3 parts of Radix Rehmanniae, 2 parts of Folium Isatidiss and Fructus Forsythiaes.
Preferably, described pharmaceutical composition also comprises the material of following weight portion: Herba basellae rubrae 5-20 part, Radix Asparagi 1-10 part, Radix Ranunculi Ternati 10-30 part, Flos Hibisci 1-5 part, Herba Limnophilae rugosae 1-20 part, Herba Violae diffusae 10-30 part, Herba Commelinae Diffusae 1-20 part, Herba Astragali Sinici 10-30 part, Flos Inulae 1-10 part, Herba Solidaginis 5-15 part, Herba Violae 10-30 part, cold certain kind of berries 1-10 part, Cacumen Myricariae Germanicae 1-5 part, Semen Sojae Preparatum seven 5-10 parts, Semen Sojae Preparatum 1-10 part, Herba Eupatorii Lindleyani 20-50 part, Herba Spilanthis Acmellae 1-10 part and Cor Cervi grass 1-10 part.
Preferably, described pharmaceutical composition also comprises the material of following weight portion: 10 parts of Herba basellae rubrae, 7 parts of Radix Asparagi, 15 parts of Radix Ranunculi Ternatis, 3 parts of Flos Hibisci, 10 parts of Herba Limnophilae rugosaes, 11 parts of Herba Violae diffusaes, 10 parts of Herba Commelinae Diffusaes, 15 parts of Herba Astragali Sinici, 5 parts of Flos Inulaes, 9 parts of Herba Solidaginiss, 15 parts of Herba Violaes, 9 parts of the cold certain kind of berries, 3 parts of Cacumen Myricariae Germanicaes, 77 parts of Semen Sojae Preparatums, 7 parts of Semen Sojae Preparatums, 30 parts of Herba Eupatorii Lindleyanis, 8 parts of Herba Spilanthis Acmellae, 9 parts of Cor Cervi grass.
Preferably, described pharmaceutical composition can be tablet, dispersible tablet, capsule, soft capsule or decoction.
Generally acknowledged that at present " organic conception ", " determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs ", " compound recipe use ", " compound compatibility medication is as used military forces " are the most scientific the most several large advantages of the traditional Chinese medical science, wherein " compound compatibility medication is as used military forces " is the original theory of Chinese medicine of very science.Each medicine tight compatibility all linked with one another as arrayed troops for battle in traditional Chinese medical science prescription is its effective means that is better than Western medicine formula.Tcm prescription theory is thought, each prescription, not only need to select the appropriate compatibility of suitable medicament according to etiology and pathogenesis, also should meet the basic structure of prescription simultaneously, the i.e. prescription compatibility theory of " monarch, minister, help, make ", the prescription compatibility of so-called " monarch, minister, help, make " is exactly that it is based upon the scientific matching on the comprehensive judgement basis of disease pathogenesis.In medical square tube cross too many levels, many target spots and integrate the biological mechanism regulating, can obtain than Western medicine more lastingly, therapeutic effect that more green natural has no side effect, and this curative effect is to be based upon on the accurate instruction of the original theory of above-mentioned traditional Chinese medical science tradition, the present invention is just following this principle.
In compositions of the present invention, Herba Spilanthis Acmellae and Cor Cervi grass are monarch drug; The Radix Astragali, Radix Angelicae Sinensis, Radix Rehmanniae, Folium Isatidis, Herba basellae rubrae, Radix Asparagi, Radix Ranunculi Ternati, Herba Violae diffusae, Herba Commelinae Diffusae are ministerial drug; Fructus Forsythiae, Flos Hibisci, Herba Limnophilae rugosae, Herba Astragali Sinici, Flos Inulae, Herba Solidaginis, Herba Violae, the cold certain kind of berries, Cacumen Myricariae Germanicae, Semen Sojae Preparatum seven, Herba Eupatorii Lindleyani are adjuvant drug; Semen Sojae Preparatum is for making medicine.Pharmaceutical composition of the present invention interacts, and synergism complements each other, play altogether the merit of monarch, thereby play the effect that good dispelling wind and heat pathogens, lung heat clearing induce sweat, detoxify and reduce phlegm, severe pulmonary infection is had to good curative effect, and its raw material is simple, with low cost, taking convenience.
The specific embodiment
Below by embodiment, further illustrate the present invention.It should be understood that embodiments of the invention are for the present invention rather than limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent otherwise in the present invention is percetage by weight.
Embodiment decoction of the present invention
Take 8 grams of the Radixs Astragali, 6 grams of Radix Angelicae Sinensis, 3 grams of Radix Rehmanniae, 2 grams of Folium Isatidiss, 3 grams of Fructus Forsythiaes, 10 grams of Herba basellae rubrae, 7 grams of Radix Asparagi, 15 grams of Radix Ranunculi Ternatis, 3 grams of Flos Hibisci, 10 grams of Herba Limnophilae rugosaes, 11 grams of Herba Violae diffusaes, 10 grams of Herba Commelinae Diffusaes, 15 grams of Herba Astragali Sinici, 5 grams of Flos Inulaes, 9 grams of Herba Solidaginiss, 15 grams of Herba Violaes, 9 grams of the cold certain kind of berries, 3 grams of Cacumen Myricariae Germanicaes, 77 grams of Semen Sojae Preparatums, 7 grams of Semen Sojae Preparatums, 30 grams of Herba Eupatorii Lindleyanis, 8 grams of Herba Spilanthis Acmellae, 9 grams of Cor Cervi grass, add 5000 ml waters, in the flask of condensing tube is housed, reflux is 3 hours, then filter, obtain filtrate 1 and filtering residue 1; 2) in filtering residue 1, add 2000 ml waters, in the flask of condensing tube is housed, heat 2 hours, filter, obtain filtrate 2 and filtering residue 2; 3) in filtering residue 2, add 1000 ml waters, in the flask of condensing tube is housed, heat 1 hour, filter, obtain filtrate 3 and filtering residue 3; And 4) merge described filtrate 1, filtrate 2 and filtrate 3, be cooled to room temperature, obtain.
Toxicity test
Acute toxicity test: 60 of application NIH mices, SPF level, male and female half and half, body weight 17～24g, carries out acute toxicity test.Mice is divided into two groups at random, and 30 every group, matched group and administration group, test front fasting 12 hours; Adjust the decoction of preparing in embodiment, making concentration is 3.68g crude drug/ml, gavage, gavage volume is 5ml/kg (being that single-dose dosage is 18.4g crude drug/kg), matched group gives equivalent normal saline, administration in a day 2 times, delivery time 6 hours, after administration, Continuous Observation is 14 days, and records toxic reaction and the death toll of mice.Experimental result shows: with matched group comparison, after administration, mice has no notable difference, experiment Continuous Observation 14 days, and mice overall health of patients, diet, drinking-water, body weight gain are all normal.Select to put to death administration group mice, test under microscope: the important organs such as the heart, liver, lung, gastric and thymus, no abnormality seen changes.Mice oral administration gavage decoction LD of the present invention
50>18.4g crude drug/kg, every day, maximum dosage-feeding was 36.8g crude drug/kg/ day.Clinical drug dosage of the present invention is 6.8g crude drug/day/people, becomes body weight for humans in 60kg, and average dosage is 0.113g crude drug/kg/ day.By weighing machine: the dosis tolerata of mice (average weight take 21g) oral administration gavage Chinese medicine of the present invention is quantity 326 times.Therefore the present invention's pharmaceutical composition acute toxicity for oral administration is low, clinical drug safety.
Long term toxicity test: application SD rat, body weight 200g ± 10g, male and female half and half.With the decoction of preparing in embodiment, test.Prepare high, medium and low three dosage groups, be respectively 300,150,75 times of clinical application amount, with the normal saline 1:1 containing 2 % by weight Radix Acaciae senegalis, mix.Adopt gastric infusion mode, 16 weeks (1.0ml/100g body weight of continuous use, every day 2 times) and drug withdrawal after 4 weeks, result shows: medicine of the present invention all has no significant effect indexs such as the hair of rat, behavior, defecation, body weight, organ weights, hemogram, hepatic and renal function, blood glucose, blood fat, internal organs naked eyes do not find that difference changes and histological examination result shows, medication 16 weeks and drug withdrawal are after 4 weeks, and each internal organs of rat are all without obviously changing.Illustrate that toxicity is little after the present invention's pharmaceutical composition for oral administration is to rat long-term prescription, after drug withdrawal, also there is no difference reaction, application safety.
Experimental example
Physical data
This organizes 200 routine patients with pneumonias from August, 2012-2014 hospital outpatient in year March, male 110 examples wherein, female's 90 examples; Age 53-76 year, average (60.2 ± 13.5) year.Diagnostic criteria is heating, continues violent cough, and x-ray finding is remarkable far beyond sign.Leukocyte normally or slightly increases mostly.Mycoplasma pneumoniae specific antibody (MP-IGM) positive or cold agglutinin IGM are positive.
Therapeutic Method
With the decoction of preparing in embodiment, treat, every day 2 times, clinical drug dosage of the present invention is 6.8g crude drug/day/people.Treatment is 10 days continuously.
Observation item
Before and after observation patient medication, body temperature changes, detects treatment front and back serum hs-CRP (CRP), peripheral blood leucocyte sum, alanine aminotransferase (ALT), aspartate amino transferase (AST), blood urea nitrogen (BUN), serum creatinine (Cr), partial pressure of oxygen (PaO
2), oxygenation index (PaO
2/ FiO
2).
Therapeutic evaluation
Recovery from illness: patient temperature is down to normally, expectorant is cultivated pathogen and is eliminated, and patient's mental status is recovered completely, and breast CT shows that pulmonary's inflammatory exudation focus absorbs >=50%; Effective: patient temperature declines to some extent, expectorant is cultivated pathogen and is partly removed or replace, and patient's mental status is obviously improved, and breast CT shows that pulmonary's inflammatory exudation focus absorbs <50%; Invalid: conditions of patients is without taking a turn for the better or increasing the weight of, and body temperature does not move back or raises, and expectorant is cultivated pathogen and do not removed, and patient's mental status is not improved, breast CT is shown front increase of pulmonary's inflammatory exudation focus.
Result
In 200 routine patients, recovery from illness 135 examples, effective 63 examples, invalid 2 examples.
Body temperature changes
Before 200 routine patient treatments, all there is in various degree heating, high hot 178 examples wherein, medium degree heat 22 examples, after medication, body temperature is all reduced to normally, is down to normal time average out to (3 ± 1.5) sky.
Other the results are shown in following table
Before and after treatment, patient is observed, do not find obvious untoward reaction.
Claims (10)
1. a pharmaceutical composition for the treatment of severe pulmonary infection, is characterized in that, the material that it comprises following weight portion: Radix Astragali 5-20 part, Radix Angelicae Sinensis 1-10 part, Radix Rehmanniae 1-5 part, Folium Isatidis 1-10 part and Fructus Forsythiae 1-5 part.
2. the pharmaceutical composition for the treatment of severe pulmonary infection according to claim 1, is characterized in that, the material that it comprises following weight portion: 3 parts of 8 parts of the Radixs Astragali, 6 parts of Radix Angelicae Sinensis, 3 parts of Radix Rehmanniae, 2 parts of Folium Isatidiss and Fructus Forsythiaes.
3. the pharmaceutical composition for the treatment of severe pulmonary infection according to claim 1 and 2, it is characterized in that, it also comprises the material of following weight portion: Herba basellae rubrae 5-20 part, Radix Asparagi 1-10 part, Radix Ranunculi Ternati 10-30 part, Flos Hibisci 1-5 part, Herba Limnophilae rugosae 1-20 part, Herba Violae diffusae 10-30 part, Herba Commelinae Diffusae 1-20 part, Herba Astragali Sinici 10-30 part, Flos Inulae 1-10 part, Herba Solidaginis 5-15 part, Herba Violae 10-30 part, cold certain kind of berries 1-10 part, Cacumen Myricariae Germanicae 1-5 part, Semen Sojae Preparatum seven 5-10 parts, Semen Sojae Preparatum 1-10 part, Herba Eupatorii Lindleyani 20-50 part, Herba Spilanthis Acmellae 1-10 part and Cor Cervi grass 1-10 part.
4. the pharmaceutical composition for the treatment of severe pulmonary infection according to claim 3, it is characterized in that, it also comprises the material of following weight portion: 10 parts of Herba basellae rubrae, 7 parts of Radix Asparagi, 15 parts of Radix Ranunculi Ternatis, 3 parts of Flos Hibisci, 10 parts of Herba Limnophilae rugosaes, 11 parts of Herba Violae diffusaes, 10 parts of Herba Commelinae Diffusaes, 15 parts of Herba Astragali Sinici, 5 parts of Flos Inulaes, 9 parts of Herba Solidaginiss, 15 parts of Herba Violaes, 9 parts of the cold certain kind of berries, 3 parts of Cacumen Myricariae Germanicaes, 77 parts of Semen Sojae Preparatums, 7 parts of Semen Sojae Preparatums, 30 parts of Herba Eupatorii Lindleyanis, 8 parts of Herba Spilanthis Acmellae, 9 parts of Cor Cervi grass.
5. the pharmaceutical composition for the treatment of severe pulmonary infection according to claim 1, is characterized in that, described pharmaceutical composition can be tablet, dispersible tablet, capsule, soft capsule or decoction.
6. the application of pharmaceutical composition in the medicine of preparation treatment severe pulmonary infection, is characterized in that the material that described pharmaceutical composition comprises following weight portion: Radix Astragali 5-20 part, Radix Angelicae Sinensis 1-10 part, Radix Rehmanniae 1-5 part, Folium Isatidis 1-10 part and Fructus Forsythiae 1-5 part.
7. application according to claim 6, is characterized in that, the material that described pharmaceutical composition comprises following weight portion: 3 parts of 8 parts of the Radixs Astragali, 6 parts of Radix Angelicae Sinensis, 3 parts of Radix Rehmanniae, 2 parts of Folium Isatidiss and Fructus Forsythiaes.
8. according to the application described in claim 6 or 7, it is characterized in that, described pharmaceutical composition also comprises the material of following weight portion: Herba basellae rubrae 5-20 part, Radix Asparagi 1-10 part, Radix Ranunculi Ternati 10-30 part, Flos Hibisci 1-5 part, Herba Limnophilae rugosae 1-20 part, Herba Violae diffusae 10-30 part, Herba Commelinae Diffusae 1-20 part, Herba Astragali Sinici 10-30 part, Flos Inulae 1-10 part, Herba Solidaginis 5-15 part, Herba Violae 10-30 part, cold certain kind of berries 1-10 part, Cacumen Myricariae Germanicae 1-5 part, Semen Sojae Preparatum seven 5-10 parts, Semen Sojae Preparatum 1-10 part, Herba Eupatorii Lindleyani 20-50 part, Herba Spilanthis Acmellae 1-10 part and Cor Cervi grass 1-10 part.
9. application according to claim 8, it is characterized in that, described pharmaceutical composition also comprises the material of following weight portion: 10 parts of Herba basellae rubrae, 7 parts of Radix Asparagi, 15 parts of Radix Ranunculi Ternatis, 3 parts of Flos Hibisci, 10 parts of Herba Limnophilae rugosaes, 11 parts of Herba Violae diffusaes, 10 parts of Herba Commelinae Diffusaes, 15 parts of Herba Astragali Sinici, 5 parts of Flos Inulaes, 9 parts of Herba Solidaginiss, 15 parts of Herba Violaes, 9 parts of the cold certain kind of berries, 3 parts of Cacumen Myricariae Germanicaes, 77 parts of Semen Sojae Preparatums, 7 parts of Semen Sojae Preparatums, 30 parts of Herba Eupatorii Lindleyanis, 8 parts of Herba Spilanthis Acmellae, 9 parts of Cor Cervi grass.
10. application according to claim 6, is characterized in that, described pharmaceutical composition can be tablet, dispersible tablet, capsule, soft capsule or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410417795.6A CN104147255A (en) | 2014-08-23 | 2014-08-23 | Pharmaceutical composition for treatment of severe pulmonary infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410417795.6A CN104147255A (en) | 2014-08-23 | 2014-08-23 | Pharmaceutical composition for treatment of severe pulmonary infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104147255A true CN104147255A (en) | 2014-11-19 |
Family
ID=51873019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410417795.6A Pending CN104147255A (en) | 2014-08-23 | 2014-08-23 | Pharmaceutical composition for treatment of severe pulmonary infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104147255A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103223124A (en) * | 2013-05-20 | 2013-07-31 | 广州市云桥生物科技有限公司 | Traditional Chinese medicine composition used for treating lobar pneumonia |
| CN103316219A (en) * | 2013-07-01 | 2013-09-25 | 周汉升 | Traditional Chinese medicinal preparation for treating phthisis and preparation method thereof |
-
2014
- 2014-08-23 CN CN201410417795.6A patent/CN104147255A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103223124A (en) * | 2013-05-20 | 2013-07-31 | 广州市云桥生物科技有限公司 | Traditional Chinese medicine composition used for treating lobar pneumonia |
| CN103316219A (en) * | 2013-07-01 | 2013-09-25 | 周汉升 | Traditional Chinese medicinal preparation for treating phthisis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 崔现军: "扶正抗毒液灌肠治疗小儿病毒性肺炎临床观察", 《中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104338078A (en) | Pharmaceutical composition for treating intrahepatic cholestasis in gestation period | |
| CN104257800B (en) | A kind of medicament of Acne treatment | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN104147544A (en) | Traditional Chinese medicinal composition for treating chronic anal cryptitis | |
| CN100544749C (en) | A kind of Chinese medicine composition for the treatment of infantile fever caused by exogenous pathogens and preparation method thereof | |
| CN104288252A (en) | Drug for treating arthralgia | |
| CN103948829A (en) | Traditional Chinese medicinal formula for treating infantile pneumonia | |
| CN104127542B (en) | A kind of pharmaceutical composition for the treatment of children's's repetitive upper respiratory tract infection | |
| CN104147255A (en) | Pharmaceutical composition for treatment of severe pulmonary infection | |
| CN104173946A (en) | Medicinal tea for treating chronic gastritis | |
| CN104096053A (en) | Medicine composition for treating infantile pneumonia | |
| CN104147184B (en) | Medicine for nursing of postpartum urinary retention | |
| CN104687032A (en) | Health caring echinacea health product | |
| CN102526248B (en) | Traditional Chinese medicine prescription capable of curing diabetes wound fester and continuously reducing blood sugar | |
| CN116726083B (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN104523854A (en) | Pharmaceutical composition for treating post-abortion menstrual disorder | |
| CN104491077A (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN102247470B (en) | A kind of Chinese medicine composition preventing and treating infant upper respiratory tract infection | |
| CN104491508A (en) | Pharmaceutical composition for treating herpes zoster | |
| CN104147423A (en) | Decoction for treating hand and foot numbness after stroke | |
| CN105902943A (en) | Medicine composition for treating wind heat cough of children | |
| CN104586914A (en) | Agent for treating fatty liver | |
| CN104664533A (en) | Preparation method of health beverage | |
| CN104306517A (en) | Preparation for treating rheumatic arthritis | |
| CN105343503A (en) | Medicine composition for treating sphagitis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141119 |
|
| WD01 | Invention patent application deemed withdrawn after publication |